Replies to post #171538 on Bioelectronics Corp (BIEL)

[4toSchool]

Demand for the good products has not been manifested to even a minimal degree. For the sake of people suffering in pain, the company should be sold to someone who can effectively market the products efficacy and create a demand for the consumable product.

[Daytime_Lantern]

Look, I'm a proponent (shareholder) of BIEL, and wish nothing but the best for the company, of course. But I'm compelled to ask the following question. So, how do you (BIEL management) have your product in position to make a huge plash all around the world, but you can't seem to get the product off its knees, why? What's going on Mr. CEO? What's wrong Mr. VP of sales? The next sentence is directed at the two aforementioned BIEL officials. Now, there are many compelling accounts, which bespeak the effectiveness of Actipatch, but you can't manage to carve a niche for it in the concomitant market, why?. Why?! Why?! Why?!... Could be used ad nauseam, when it comes to BIEL!

GLTA!!!

[gimmee greenbacks]

I disagree we all know the pps went down because of the FDA's erroneous decision in November. The newest
submission in regards to RecoveryRX is different in that it has a predicate for post op healing with the FDA's
previous approval for blepharoplasty. When clearance is given on one or both 510k applications you will see a
corresponding hike in the pps. Then I think it BIEL would be a very attractive acquisition for a large medical device company. What would the pps be then ? hmmmm